Dostarlimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 ((PD-1  programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.18 KD.